Computed tomography-guided implantation of $^{125}$I radioactive seeds in patients with malignant airway compression induced by advanced lung cancer: effectiveness and safety in 40 patients

Zhiyou Zhao, MD, Wang Yao, MD, Tao Zhang, MD, Shixin Chen, MD, Wei Fu, MD, Lijun Chen, MD, Yonggang Ma, MD, Jianzhuan Wang, MD, Mingjian Lu, MD, Dechao Jiao, MD

1 Department of Medical Imaging, 3201 Hospital of Xi'an Jiaotong University Health Science Center, Hanzhong, P.R. China, 2 Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China, 3 Department of Interventional Radiology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, P.R. China, 4 Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P.R. China

Abstract

Purpose: To evaluate the safety and efficacy of computed tomography (CT)-guided $^{125}$I radioactive seed implantation in patients with malignant airway compression induced by advanced lung cancer.

Material and methods: Between June 2015 and June 2018, 40 patients from three medical institutions with malignant airway compression induced by advanced lung cancer were treated with $^{125}$I seed implantation. The outcomes were measured in technical success and safety, objective response rate, complications, Karnofsky performance status (KPS) score, and survival time.

Results: All 40 patients successfully underwent implantation procedure. No procedure-associated death occurred. The most common complications were irritable cough, temporary hemoptysis, chest pain, fever, and pneumothorax, which occurred in 26 (65.0%), 31 (77.5%), 12 (30.0%), 15 (37.5%), and 11 (27.5%) patients, respectively. The objective response rates were 100%, 100%, 100%, 87.5%, and 83.3% at the 3rd, 6th, 12th, 24th, and 36th months post-procedure, respectively. The KPS score significantly improved at post-procedure. Median survival time was 25.1 months. Actuarial survival rates were 100%, 60%, and 15% at the 12th, 24th, and 36th months after the procedure, respectively.

Conclusions: For patients with malignant airway compression induced by advanced lung cancer, implantation with $^{125}$I seed is a safe and effective alternative treatment option.

Key words: lung cancer, $^{125}$I seed, brachytherapy, malignant airway compression, safety.

Purpose

Lung cancer is among the most prevalent cancers and the leading cause of cancer-related deaths worldwide [1,2]. In China, both incidence and mortality rates of lung cancer had a dramatic increase in the past three decades [3]. Malignant airway stenosis appeared in 20-30% cases of lung cancer, resulting in dyspnea, decreased functional status, and asphyxiation risk [4]. The development of airway stenosis could be associated with intraluminal tumor or compression from outside the tumor [5]. Since surgery was usually not feasible in this situation, palliative intervention was generally utilized to dilate the airway to improve patients' life quality and the efficacy of anti-tumor therapy. In recent years, various palliative modalities, such as electrocautery, laser therapy, stenting, argon plasma coagulation, cryotherapy, photodynamic therapy, and brachytherapy have been used for relieving airway stenosis [6,7,8,9]. Typically, the choice of therapy was based on the type and location of airway stenosis, pulmonary function, comorbidities, previous treatments, and life expectancy. Recently, $^{125}$I radioactive seed implantation had proved its efficacy in various malignant tumors [10,11,12,13]. The results of Lu et al. revealed that trans-bronchoscopy $^{125}$I radioactive seed implantation could improve the survival and quality of life of patients with pulmonary atelectasis induced by intraluminal tumors.
nal airway obstruction [14]. However, studies on the efficacy of computed tomography (CT)-guided $^{125}\text{I}$ radioactive seed implantation in patients with malignant airway compression (MAC) related to advanced lung cancer are still rare.

This present study aimed to evaluate the feasibility, safety, and efficacy of CT-guided $^{125}\text{I}$ radioactive seed implantation in dilating occluded airway and improving the quality of life in patients with advanced lung cancer related to MAC, due to tumor outside or metastatic lymph nodes.

**Material and methods**

**Ethics**

Written informed consent was obtained from all patients. Patients were sufficiently informed of the risks, benefits, and alternatives of $^{125}\text{I}$ brachytherapy. This study followed the ethical guidelines of the 1975 Declaration of Helsinki (revised in Brazil in 2013). This retrospective study was approved by the ethical committee of 3201 Affiliated Hospital of Medical College of Xi’an Jiaotong University, First Affiliated Hospital, Sun Yat-Sen University and Affiliated Cancer Hospital of Guangzhou Medical University.

**Patients**

From June 2015 to June 2018, a total of 89 patients with stage III-V airway stenosis received $^{125}\text{I}$ radioactive seed implantation in Departments of Interventional Radiology in the three institutions mentioned above. The grade of stenosis was classified as 5 grade scale on the cross-sectional CT imaging area [15]: grade 0 (non-stenosis), grade 1 (1-25% stenosis), grade 2 (26-50% stenosis), grade 3 (56-75% stenosis), grade 4 (76-90% stenosis), and grade 5 (91-100% stenosis). Inclusion criteria for this retrospective study were as follows: 1. Patients diagnosed with primary lung cancer confirmed by pathological examination; 2. Type of airway stenosis confirmed as MAC by both clinicians and radiologists; 3. Patients with at least one complete follow-up record post-implantation. Exclusion criteria for this study were as follows: 1. Patients diagnosed with other tumors (n = 22); 2. Patients diagnosed as primary endotracheal tumor (n = 16); 3. Patients with simultaneous tracheobronchial fistula (n = 7); 4. History of local radiotherapy (n = 4).

$^{125}\text{I}$ brachytherapy

The parameters of the $^{125}\text{I}$ seed (CIAE-6711) used in this study was: 4.5 mm length, 0.8 mm diameter and 3.0 × 0.5 mm inside the silver column (adsorption of $^{125}\text{I}$ seed: radioactivity, 0.8 mCi; average energy, 27-35 KeV; half-life, 59.6 days; half-layer, 0.25 mm of lead; initial dose rate, 7 cGy/h) and 0.05 mm of external titanium wall.

For targeting areas of interest, 5-mm section from CT images were obtained before $^{125}\text{I}$ brachytherapy. For each patient, a treatment plan was made using a computerized planning system (BT-RSI model TPS; YuanBo, Beijing, China) to determine the dose, number, and locations of radioactive seeds. The prescription dose varied in different institutions, ranging 100-130 Gy.

The implantation was performed in all targeted lesions of treatment section. The brachytherapy applicator’s position on the surface of patient’s body was marked by the preoperative plan based on the treatment planning system. After the induction of local anesthesia (5-15 ml of 1% lidocaine), an 18-gauge applicator was inserted into the lesion and positioned against its deepest margin using CT guidance. The applicator for implantation was attached with a turntable or clip implant gun. A CT scan was performed after implantation to assess whether $^{125}\text{I}$ distribution was consistent with the preoperative plan. If not, a supplemental implantation would be performed. Steroids were not routinely administrated post-implantation. However, if the tumor volume was large and required multiple punctures, or the airway compression was at higher level, steroids, such as dexamethasone, were administrated appropriately post-implantation, usually for no more than three days. In other words, the use of steroids depended on the clinician’s judgment. Three typical cases are presented in Figures 1 and 2.

**Concurrent therapy**

All patients were recommended chemotherapy, targeted therapy, immunotherapy, or even clinical trials of anti-tumor drugs post-$^{125}\text{I}$ seed implantation, when meeting indications.

**Follow-up**

Contrast-enhanced CT images were obtained monthly in the first 3 months post-procedure, and then at 3-month intervals for all patients. Generally, positron emission tomography (PET)-CT scan was performed with the need to evaluate tumor recurrence or metastasis, which could not be found using conventional contrast-enhanced CT image. In addition, all patients were clinically evaluated through history and physical examination at each follow-up visit. Moreover, patients were assessed to determine their Karnofsky performance status (KPS) score. The objective response rate of $^{125}\text{I}$ brachytherapy was based on the Response Evaluation Criteria in Solid Tumors (known as RECIST). In this study, major complications were defined as complication with more than 5% of incidence. Severe complication was defined as life-threatening complication, which needed urgent medical intervention.

**Quality of life**

The quality of life (QoL) assessment data of all patients were obtained with KPS score. KPS measurements ranged from 0 to 100, with higher score indicating higher QoL. Clinicians determined KPS score prior to CT-guided $^{125}\text{I}$ radioactive seed implantation and at each subsequent follow-up visit.

**Statistical analysis**

In this study, the decline in stenosis grade of MAC and the local control of tumor, which caused MAC were considered as co-primary ending points of the study, and the other main observations included technological success, safety, and efficacy of $^{125}\text{I}$ seed implantation as well as QoL. Overall survival (OS) was the second observations defined as the time span from the date of $^{125}\text{I}$ brachytherapy implantation to the date of patient’s death from any reason.
Fig. 1. Patient with MAC treated with seeds implantation and outcome. A) Preoperative enhanced scanning, location and size of neck mass, grade 4 of compression of trachea. B, C) Pre-TPS showed a peripheral matching dose of 110 Gy, 17 seeds were planned. D) Procedure of \(^{125}\)I seeds implantation. E) 3-month post-implantation, grade 2 of compression of trachea. F) 6-month post-implantation, still grade 2 of compression of trachea. G) 12-month post-implantation, grade 1 of compression of trachea. H) 18-month post-implantation, grade 0 of compression of trachea.
OS was recorded from the treatment date till the last date of contact. Kaplan-Meier analysis was used to calculate the survival data. Statistical software (SPSS 20.0; SPSS, Chicago, USA) was utilized for performing statistical analysis. $P$-values less than 0.05 were considered statistically significant.

**Results**

**Patients and procedures**

Between June 2015 and June 2018, 40 patients were finally included into the present study, with 28 males and 12 females, median age of 57.9 years. A total of 40 $^{125}$I radioactive seed implantation sessions were performed. The average number of $^{125}$I seeds used per patient was 28.3 (range, 15-45 seeds). The average diameter of the tumor was 4.1 cm (range, 2.8-5.8 cm). Baseline characteristics of all patients are shown in Table 1. The average time of procedure was 66 min (range, 30-90 min). In this study, all interventional procedures were successfully performed and well tolerated. No procedure-associated death occurred, and no patient required an urgent discontinuation of the implantation procedure.

**Airway obstruction control**

Overall, the stenosis grade of the airway obstruction declined in most patients between the procedure and the
last follow-up. At 12 months after the procedure, stenosis grade in 22 (55%) patients became grade 0, while others turn out to be grade 1 (Table 2). The objective response rate (ORR) of local tumor in patients’ survival, calculated as the sum of the complete response (CR) and partial response (PR) was 80%, 100%, 100%, 100%, 87.5%, 83.3% in patients at 1st, 3rd, 6th, 12th, 24th, and 36th months, respectively. There were only 4 patients (10%) with local progress during the follow-up time. Local control of tumor, which caused airway compression is characterized in Table 3.

**Quality of life response**

In the majority of patients, KPS scores had improved after implantation, especially in those with a lower KPS score before the treatment. The improvement in symptoms and well-being started in the first month post-procedure and was maintained until the final follow-up in most of the patients. Mean KPS score was 71.4 ±4.8 before surgery and increased to 86.2 ±3.8, 85.9 ±5.1, 84.3 ±4.4, 83.1 ±4.8 at 6, 12, 24, 36 months after the procedure, respectively. There was a significant improvement between pre-procedure and six months post-procedure KPS scores ($p < 0.0001$), while there was no significant improvement among post-procedure KPS scores.

**Survival analysis**

The median follow-up time was 30.3 months (range, 12-41 months), the median survival time was 25.1 months, and the survival rate was 100% at 12 months, 60% at 24 months, and 15% at 36 months after the procedure. At the time of analysis, 34 patients died, and 32 patients died of primary disease progression, including local recurrence and distant metastasis. One patient died of respiratory failure, with a history of COPD, and 1 patient died of myocardial infarction, with a history of hypertension and diabetes mellitus. Outcomes of survival are reported in Figure 3.

**Complication**

In this study, all patients tolerated the procedure well and no procedure-related death occurred. Complications with an incidence ≥ 10% included irritable cough, temporary hemoptysis, chest pain, fever, pneumothorax, pneumonia, and air leak, which occurred in 26 (65.0%), 31 (77.5%), 12 (30.0%), 15 (37.5%), 11 (27.5%), 6 (15%), and 4 (10%) patients, respectively. One patient suffered from chest pain for more than a week, with an increased leukocyte level and was suspected of mediastinitis; the complication was resolved with antibiotics administration. No patients required additional emergency intervention treatment. Detailed information is shown in Table 4.

**Discussion and conclusions**

Malignant airway stenosis presented in late-stage lung cancer has a dismal long-term survival, with < 1% of five-year survival rate [1]. Systemic chemotherapy considered as standard therapy for late-stage lung cancer could be unbearable for patients with poor performance status and not provide immediate recanalization for airway stenosis [16]. Therefore, external beam radiation therapy (EBRT) is recommended as palliative treatment in such cases. However, the result of EBRT is usually unpredictable, with possible aggravation of airway obstruction related to early tumor edema [17]. Recently, a variety of bronchoscopic techniques are available for the treatment of airway stenosis [5,6,7,8,9]. Unfortunately, there is a high, 24% rate of stent re-stenosis within 3 months due to in-growth of initial malignancy. Moreover, a placement with stent re-stenosis offers limited survival benefits in the absence of locoregional therapy for endobronchial lesions. Recently, a novel therapy with $^{125}$I seed was developed and exhibited promising outcomes in lung cancer [10,12,13].

---

**Table 1.** Background characteristics of patients before $^{125}$I seed implantation ($N = 40$)

| Patient characteristic | Value |
|------------------------|-------|
| Gender, $n$ (%)        |       |
| Male                   | 28 (70.0) |
| Female                 | 12 (30.0) |
| Age, years             |       |
| Median                 | 57.9  |
| Range                  | 32-76  |
| Pathology type, $n$    |       |
| Squamous cell cancer   | 17    |
| Adenocarcinoma cell cancer | 23 |
| Main clinical presentation, $n$ |   |
| Respiratory distress   | 34    |
| Cough                  | 26    |
| Infection              | 5     |
| Obstructive location, $n$ |     |
| Right bronchus         | 12    |
| Left bronchus          | 17    |
| Main bronchus          | 11    |
| Clinical stage, $n$    |       |
| IIIa                   | 8     |
| IIIb                   | 7     |
| IIIc                   | 12    |
| IVa                    | 9     |
| IVb                    | 4     |
| Stenosis grade         |       |
| III                    | 14    |
| IV                     | 26    |
In the present study, we also confirmed that CT-guided 125I implantation was safe and efficient in MAC patients.

In low-dose-rate (LDR) therapies, brachytherapy delivery requires < 1 Gy per hour for permanent placement of radioactive sources, while in high-dose-rate (HDR) therapies, radiation is delivered over several courses [18]. In previous reports with HDR brachytherapy, isotope iridium-192 (192Ir) was used for airway malignancy, with dose regimens ranging from 4 treatments with 5 Gy each to 2 treatments with 15 Gy each [19]. However, in this study, 125I seed was employed as brachytherapy source, with a prescribed dose of 100-130 Gy. Moreover, intra-

In the present study, we also confirmed that CT-guided 125I implantation was safe and efficient in MAC patients.
luminal HDR brachytherapy to a certain extent was not suitable for patients with MAC from outside the tumor. Continuous LDR brachytherapy with $^{125}$I seeds could contribute to an increase in radiation damage of radiosensitive G$_{2-M}$ phase tumor cells [20]. Furthermore, LDR brachytherapy with $^{125}$I seeds allows for efficient repair of normal tissue with sublethal radiation damage [21]. In the present study, the technical success rate of $^{125}$I seed implantation was 100% and no $^{125}$I seed loss occurred in the delivery. During the follow-up time, the patients tolerated $^{125}$I seed implantation well, which could be due to a reasonable choice of isotope, sophisticated design of TPS plan system, and precise technique of implantation presented by experienced interventional radiologists.

Objective response rates of targeted lesion were 100%, 100%, 100%, 87.5%, and 83.3% at 3$^{rd}$, 6$^{th}$, 12$^{th}$, 24$^{th}$, and 36$^{th}$ months post-procedure, respectively. Compared with a previous study [19], recanalization obstruction in our study demonstrated similar satisfying effects with longer duration. Possible reason could be due to more sustainable therapeutic effect of $^{125}$I radioactive seed implantation. The majority of patients in the present study showed improved KPS score after the implantation procedure. The mean KPS score was 71.4 ± 4.8 before procedure and improved to 86.2 ± 3.8 at six months after implantation ($p < 0.0001$). The sustaining therapeutic effect of $^{125}$I radioactive seed implantation could be responsible for the comparatively long duration of KPS improvement.

The median survival was 25.1 months, and the survival rates were 100% at the 12$^{th}$ month, 60% at the 24$^{th}$ month, and 15% at the 36$^{th}$ month. The two-year survival rate was higher in the current study compared with a previous study with HDR intraluminal brachytherapy [22]. The difference may result from patients’ selection or additional therapies, such as chemotherapy, immuno-therapy, and targeted therapy. Overall, 60% 2-year survival rate was a favorable outcome for the present study, in which most patients presented with advanced stage disease.

While complications of HDR intraluminal brachytherapy were generally moderate, severe complications, including fatal hemoptysis and broncho-esophageal fistula were still occasionally observed [23,24]. Compared with HDR, LDR presented better relative biological effect (RBE) [25,26]. In the present study, treatment complications observed were mild, mainly presenting as a temporary increase in irritable cough, transient hemoptysis, chest pain, fever, and pneumothorax, which were resolved with few additional therapies. No severe complications were noted. Therefore, $^{125}$I seed implantation brachytherapy could be a preferable treatment option with regards to complications and could be repeated whenever indicated [27].

This study had several limitations. Firstly, it was a retrospective non-control study, and cautious interpretation of the results are needed. Secondly, affected by the experience of operating interventional radiologists in different institutions, the precise positioning of radioactive seed designed by a preoperative plan of TPS was occasionally challenging. Lastly, the current study involved small cohort of patients, which undermine the conclusion.

In conclusion, the implantation of $^{125}$I seeds can be a safe and effective alternative therapy for patients with inoperable MAC. It presents excellent local control efficacy, with moderate side effects and acceptable tolerability. Nevertheless, a comprehensive evaluation of the long-term effects of $^{125}$I seed implantation treatment is still needed.

**Funding**

The study was supported by No. 20191A011098, Western Medicine General Guide Project of Guangzhou Municipal Health Commission, No. 20202112, Project of Administration of Traditional Chinese Medicine of Guangdong Province of China.

**Disclosure**

The authors report no conflict of interest.

**References**

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer a review. JAMA 2019; 322: 764-774.
3. Au WW, Su D, Yuan J et al. Cigarette smoking in China: Public health, science, and policy. Rev Environ Health 2012; 27: 4349.
4. Ernst A, Feller-Kopman D, Becker HD et al. Central airway obstruction. Am J Respir Crit Care Med 2004; 169: 1278-1297.
5. Mahajan AK, Ibrahim O, Perez R et al. Electrosurgical and laser therapy tools for the management of malignant central airway obstructions. Chest 2020; 157: 446-453.
6. Wahidi MM, Unroe MA, Adlakha N et al. The use of electrocautery as the primary ablative modality for malignant and benign airway obstruction. J Thorac Oncol 2011; 6: 1516-1520.
7. Ost DE, Ernst A, Grosu HB et al. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. Chest 2015; 147: 1282-1298.
8. Cavaliere S, Venuta F, Foccoli P et al. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest 1996; 110: 1536-1542.
9. Wang Y, Lu J, Guo HJ et al. A novel trackechobronchial stent loaded with $^{125}$I seeds in patients with malignant airway obstruction compared to a conventional stent: a prospective randomized controlled study. Ebiomeditice 2018; 33: 269-275.
10. Ji Z, Sun H, Jiang Y et al. Comparative study for CT-guided I seed implantation assisted by 3D printing coplanar and non-coplanar template in peripheral lung cancer. J Contemp Brachytherapy 2019; 11: 169-173.
11. Lu M, Yao W, Zhang T et al. Feasibility and efficacy of microwave ablation combined with iodine - 125 seed implantation in local control of recurrent retroperitoneal liposarcomas: initial clinical experience. Oncologist 2017; 22: 1500-1505.
12. Zhang T, Lu M, Peng S et al. CT-guided implantation of radioactive125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol 2014; 140: 1383-1390.
13. Doggett SW, Chino S, Lempert T. A novel approach for salvage treatment of non-small-cell lung cancer: percutaneous CT fluoroscopy-guided permanent seed brachytherapy for salvage treatment of lung cancer: long-term results of a case series. J Contemp Brachytherapy 2019; 11: 174-179.
14. Lu M, Pu D, Zhang W et al. Trans-bronchoscopy with implantation of $^{125}$I radioactive seeds in patients with pulmonary atelectasis induced by lung cancer. Oncol Lett 2015; 10: 216-222.

15. Freitag L, Ernst A, Unger M et al. A proposed classification system of central airway stenosis. Eur Respir J 2007; 30: 7-12.

16. Celikoglu F, Celikoglu SI, Goldberg EP et al. Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer 2008; 61: 1-12.

17. Rochet N, Hauswald H, Schmaus M et al. Safety and efficacy of thoracic external beam radiotherapy after airway stenting in malignant airway obstruction. Int J Radiat Oncol Biol Phys 2012; 83: 129-135.

18. Pang H, Wu K, Shi X et al. Hypofractionated 192Ir source stereotactic ablative brachytherapy with coplanar template assistance in the primary treatment of peripheral lung cancer. J Contemp Brachytherapy 2019; 4: 370-378.

19. Escobar-Sacristan JA, Granda-Orive JL, Gutierrez Jimenez T et al. Endobronchial brachytherapy in the treatment of malignant lung tumours. Eur Respir J 2004; 24: 348-352.

20. Qu A, Wang H, Li J et al. Biological effects of $^{125}$I seeds radiation on a 549 lung cancer cells: G2/M arrest and enhanced cell death. Cancer Invest 2014; 32: 209-217.

21. Chen Z, Nath R. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. Int J Radiat Oncol Biol Phys 2003; 55: 825-834.

22. Hennequin C, Bleichner O, Trédaniel J et al. Longterm results of endobronchial brachytherapy: A curative treatment? Int J Radiat Oncol Biol Phys 2007; 67: 425430.

23. Kubaszewska M, Skowronek J, Chicheł A et al. The use of high dose rate endobronchial brachytherapy to palliate symptomatic recurrence of previously irradiated lung cancer. Neoplasma 2008; 55: 239245.

24. Ozkok S, Karakoyun Celik O, Goksel T et al. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients. Lung Cancer 2008; 62: 326333.

25. Wang J, Wang J, Liao A et al. The direct biologic effects of radioactive $^{125}$I seeds on pancreatic cancer cells PANC1, at continuous lowdose rates. Cancer Biother Radiopharm 2009; 24: 409416.

26. Liao A, Wang J, Wang J et al. Relative biological effectiveness and cellkilling efficacy of continuous lowdoserate $^{125}$I seeds on prostate carcinoma cells in vitro. Int J Cancer Ther 2010; 9: 5965.

27. Li J, Zhang J, Xie Q et al. How many times $^{125}$I seed implantation brachytherapy can be repeated for pulmonary metastases: clinical efficacy and complications. J Contemp Brachytherapy 2019; 11: 35-40.